C.R. Bard (BCR) Shares are Down -2.45%

C.R. Bard (BCR) has risen sharply, recording gains of 1.39% in the past 4 weeks. However, the stock has corrected -2.45% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 1.94% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 0.48% and the 50-Day Moving Average is 0.82%.The 200 Day SMA reached 7.3%


C.R. Bard (NYSE:BCR): After opening at $224.59, the stock dipped to an intraday low of $221.95 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $225.04 and the buying power remained strong till the end. The stock closed at $224.28 for the day, a gain of 0.24% for the day session. The total traded volume was 610,488. The stocks close on the previous trading day was $224.28.

C.R. Bard (BCR) : The highest short term price target forecast on C.R. Bard (BCR) is $264 and the lowest target price is $225. A total of 10 equity analysts are currently covering the company. The average price of all the analysts is $240.6 with a standard deviation of $11.28.

C. R. Bard, Inc. (Bard) and its subsidiaries are engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. . The Company reports its sales in four major product group categories: vascular, urology, oncology and surgical specialty. The Company also has a product group of other products. The Companys vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and heart arrhythmias. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and other soft tissue repairs, in addition to hemostats and surgical sealants.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.